Nxera Pharma Co (STU:JSS) Ending Cash Position : €285.6 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Nxera Pharma Co Ending Cash Position?

Nxera Pharma Co's Ending Cash Position for the quarter that ended in Mar. 2024 was €285.6 Mil.

Nxera Pharma Co's quarterly Ending Cash Position increased from Sep. 2023 (€268.6 Mil) to Dec. 2023 (€312.5 Mil) but then declined from Dec. 2023 (€312.5 Mil) to Mar. 2024 (€285.6 Mil).

Nxera Pharma Co's annual Ending Cash Position declined from Dec. 2021 (€467.2 Mil) to Dec. 2022 (€465.7 Mil) and declined from Dec. 2022 (€465.7 Mil) to Dec. 2023 (€312.5 Mil).

Nxera Pharma Co Ending Cash Position Historical Data

The historical data trend for Nxera Pharma Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Ending Cash Position Chart

Nxera Pharma Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

126.83

316.84

467.15

465.70

312.49

Nxera Pharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															462.15	428.32	268.63	312.49	285.64

Nxera Pharma Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nxera Pharma Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	423.894	+	-111.405
	=	312.5

Nxera Pharma Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	301.296	+	-15.659
	=	285.6

Nxera Pharma Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co (STU:JSS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (STU:JSS) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

SOLTF:USA 4565:Japan

Address

2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083

Website

http://www.sosei.com

Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (STU:JSS) Headlines

No Headlines